Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
30.19
-0.84 (-2.71%)
At close: Aug 26, 2026, 4:00 PM EDT
30.00
-0.19 (-0.63%)
Pre-market: Aug 27, 2026, 9:01 AM EDT
Beam Therapeutics Revenue
Beam Therapeutics had revenue of $490.00K in the quarter ending June 30, 2026, a decrease of -94.21%. This brings the company's revenue in the last twelve months to $156.04M, up 158.88% year-over-year. In the year 2025, Beam Therapeutics had annual revenue of $139.74M with 120.01% growth.
Revenue (ttm)
$156.04M
Revenue Growth
+158.88%
P/S Ratio
19.33
Revenue / Employee
$288,954
Employees
540
Market Cap
3.02B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 139.74M | 76.23M | 120.01% |
| Dec 31, 2024 | 63.52M | -314.19M | -83.18% |
| Dec 31, 2023 | 377.71M | 316.79M | 520.01% |
| Dec 31, 2022 | 60.92M | 9.08M | 17.51% |
| Dec 31, 2021 | 51.84M | 51.82M | 215,916.67% |
| Dec 31, 2020 | 24.00K | 6.00K | 33.33% |
| Dec 31, 2019 | 18.00K | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Arcutis Biotherapeutics | 463.98M |
| Zai Lab | 449.61M |
| Precigen | 85.72M |
| Viridian Therapeutics | 71.13M |
| Nurix Therapeutics | 36.77M |
| Alumis | 7.40M |
| AtaiBeckley | 4.47M |
BEAM News
- 20 days ago - Beam Therapeutics price target lowered to $43 from $47 at BofA - TheFly
- 22 days ago - Beam Therapeutics price target raised to $78 from $75 at Canaccord - TheFly
- 23 days ago - Beam Therapeutics reports Q2 EPS ($1.18), consensus ($1.13) - TheFly
- 23 days ago - Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire
- 23 days ago - Beam Therapeutics Earnings release: Q2 2026 - Filings
- 23 days ago - Beam Therapeutics Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 - GlobeNewsWire
- 7 weeks ago - Beam Therapeutics Slides: Conference presentation - Filings